Pfizer rose 1.19% to Rs 1,098 at 10:37 IST on BSE after net profit rose 20.9% to Rs 58.16 crore on 0.2% growth in net sales to Rs 252.19 crore in Q4 March 2013 over Q4 March 2012.
The Q4 result was announced after market hours on Tuesday, 14 May 2013.
Meanwhile, the S&P BSE Sensex was up 305.98 points or 1.55% at 20,028.27.
On BSE, 873 shares were traded in the counter as against average daily volume of 1,429 shares in the past one quarter.
The stock hit a high of Rs 1,106 and a low of Rs 1,095 so far during the day. The stock had hit a 52-week high of Rs 1,361 on 12 September 2012. The stock had hit a 52-week low of Rs 993 on 12 April 2013.
The stock had outperformed the market over the past one month till 14 May 2013, surging 8.23% compared with the Sensex's 8.11% rally. The scrip had, however, underperformed the market in past one quarter, declining 1.77% as against Sensex's 1.15% rise.
The mid-cap pharma firm has equity capital of Rs 29.84 crore. Face value per share is Rs 10.
Pfizer's net profit jumped 172.6% to Rs 503.20 crore on 6.8% decline in net sales to Rs 947.98 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).
Pfizer's board of directors at a meeting held on Tuesday, 14 May 2013, recommended a normal dividend of Rs 12.50 per share and special dividend of Rs 20 per share on account of sale of animal health business aggregating to a total dividend of Rs 32.50 per share for FY 2013.
Pfizer's pharmaceuticals product portfolio spans a wide range of therapeutic classes from vitamins supplements and nutritional to antibiotics and cardiovascular.
Powered by Capital Market - Live News
